AbbVie Inc. (NYSE:ABBV) insider Henry O. Gosebruch sold 18,300 shares of the business’s stock in a transaction on Monday, October 30th. The shares were sold at an average price of $90.55, for a total value of $1,657,065.00. Following the completion of the sale, the insider now owns 81,287 shares of the company’s stock, valued at $7,360,537.85. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Shares of AbbVie Inc. (NYSE:ABBV) traded down 0.78% during trading on Tuesday, reaching $90.25. The company’s stock had a trading volume of 7,059,309 shares. AbbVie Inc. has a 12-month low of $55.06 and a 12-month high of $98.26. The stock has a market cap of $143.87 billion, a P/E ratio of 22.20 and a beta of 1.51. The stock’s 50-day moving average is $89.93 and its 200-day moving average is $75.20.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 27th. The company reported $1.41 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.39 by $0.02. AbbVie had a return on equity of 164.66% and a net margin of 24.38%. The business had revenue of $7 billion for the quarter, compared to the consensus estimate of $7 billion. During the same quarter last year, the business posted $1.21 earnings per share. The company’s revenue for the quarter was up 8.8% on a year-over-year basis. Equities research analysts anticipate that AbbVie Inc. will post $5.54 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be given a dividend of $0.71 per share. This is an increase from AbbVie’s previous quarterly dividend of $0.64. The ex-dividend date of this dividend is Thursday, January 11th. This represents a $2.84 dividend on an annualized basis and a yield of 3.15%. AbbVie’s dividend payout ratio (DPR) is presently 62.29%.

TRADEMARK VIOLATION WARNING: “AbbVie Inc. (ABBV) Insider Sells $1,657,065.00 in Stock” was posted by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was stolen and republished in violation of US and international copyright laws. The correct version of this news story can be accessed at

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ABBV. Acropolis Investment Management LLC purchased a new stake in AbbVie during the second quarter valued at about $106,000. Franklin Parlapiano Turner & Welch LLC purchased a new stake in AbbVie during the first quarter valued at about $108,000. Hudock Capital Group LLC raised its position in AbbVie by 109.5% during the second quarter. Hudock Capital Group LLC now owns 1,542 shares of the company’s stock valued at $111,000 after purchasing an additional 806 shares in the last quarter. Ffcm LLC raised its position in AbbVie by 167.2% during the second quarter. Ffcm LLC now owns 1,539 shares of the company’s stock valued at $111,000 after purchasing an additional 963 shares in the last quarter. Finally, Bristlecone Advisors LLC purchased a new stake in AbbVie during the third quarter valued at about $113,000. Institutional investors and hedge funds own 68.49% of the company’s stock.

A number of analysts have recently weighed in on the company. Piper Jaffray Companies reiterated a “buy” rating and set a $85.00 target price on shares of AbbVie in a research report on Thursday, August 3rd. Evercore ISI assumed coverage on AbbVie in a research report on Wednesday, August 16th. They set an “outperform” rating and a $95.00 target price for the company. Leerink Swann upgraded AbbVie from a “market perform” rating to an “outperform” rating and upped their target price for the company from $89.00 to $106.00 in a research report on Monday, October 2nd. SunTrust Banks, Inc. reiterated a “buy” rating on shares of AbbVie in a research report on Monday. Finally, BidaskClub downgraded AbbVie from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Eight equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $93.68.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Insider Buying and Selling by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with's FREE daily email newsletter.